Research & Development

PUBLICATIONS

Schröder, U. and Sabel, B. A.
Nanoparticles, a drug carrier system to pass the blood brain barrier, permit central analgesic effects of i.v. dalargin injections.
Brain Res. 1996, 710:121-124.

Sommerfeld, P., Schröder, U. and Sabel, B. A.
Long-term stability of PBCA nanoparticle suspensions suggests clinical usefulness.
Int. J. Pharm. 1997, 155:201-207.

Sommerfeld, P., Schröder, U. and Sabel, B. A.
Sterilization of unloaded polybutylcyanoacrylate nanoparticles.
Int. J. Pharm. 1998, 164: 113-118.

Schröder, U., Sommerfeld, P. and Sabel, B. A.
Efficacy of oral dalargin-loaded nanoparticle delivery across the blood brain barrier.
Peptides 1998, 19:777-780.

Schröder, U., Sommerfeld, P. Ulrich, S. and Sabel, B. A.
Nanoparticle technology for delivery of drugs across the blood brain barrier.
J. Pharm. Sci. 1998, 87:1305-1307.

Kreuter, J. et al.
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood brain barrier.
J. Drug Targeting 2002, 4: 317-325.

Kreuter, J. et al.
Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of the drug to the nanoparticle.
Pharmaceutical Res. 2003, 20 (3): 409-416.

Ringe, K., Walz, C. M. and Sabel, B. A.
Nanoparticle Drug Delivery to the Brain.
Encyclopedia of Nanoscience and Nanotechnology 2004, 7:91-104.

Ringe, K.
Transport of Doxorubicin Across the Blood Brain Barrier using Biologically- Compatible Polymeric Nanoparticles: A Review
Drug Delivery Report; Pharma Ventures 2006, Autumn/Winter, 38-43

Ringe, K.
Gene Delivery Across the Blood Brain barrier
Innovations in Pharmaceutical Technology 2007; Autumn 64-66